An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.

Quality of life of patients after retropubic prostatectomy - pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. Health Qual Life Outcomes (2011) 1.55

Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments. BJU Int (2015) 1.50

Daily life and life quality 3 years following prostate cancer treatment. BMC Nurs (2013) 1.45

Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst (2014) 1.42

Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system. J Med Internet Res (2013) 1.04

Measurement equivalence and feasibility of the EORTC QLQ-PR25: paper-and-pencil versus touch-screen administration. Health Qual Life Outcomes (2014) 0.99

Study protocol of the SWORD-study: a randomised controlled trial comparing combined online and face-to-face cognitive behaviour therapy versus treatment as usual in managing fear of cancer recurrence. BMC Psychol (2015) 0.92

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol (2013) 0.85

The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat Rev Urol (2012) 0.84

Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res (2014) 0.84

Establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions: the Prostate Cancer Treatment, your experience (PiCTure) study. BMJ Open (2015) 0.82

U-CARE: Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer--a clinical trial protocol. BMC Cancer (2013) 0.82

A randomised controlled trial of a cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN): trial protocol. BMC Cancer (2012) 0.81

The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer (2013) 0.81

Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. Prostate Cancer (2014) 0.80

Development and evaluation of Korean version of Quality of Sexual Function (QSF-K) in healthy Korean women. J Korean Med Sci (2014) 0.79

Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health Qual Life Outcomes (2012) 0.78

Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin. BMC Med Inform Decis Mak (2013) 0.78

Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. Radiat Oncol (2015) 0.78

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism? BMC Urol (2016) 0.77

Implementation and scientific evaluation of rehabilitative sports groups for prostate cancer patients: study protocol of the ProRehab Study. BMC Cancer (2012) 0.76

Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). BMJ Support Palliat Care (2017) 0.76

Quality of life in penile carcinoma patients - post-total penectomy. Cent European J Urol (2016) 0.75

Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. BMJ Open (2016) 0.75

Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol. BMC Cancer (2017) 0.75

Patient Reported Outcome Measure (PROM) of Quality of Life After Prostatectomy - Results from a 5-Year Study. Open Nurs J (2013) 0.75

Associations of objectively measured moderate-to-vigorous physical activity and sedentary behavior with quality of life and psychological well-being in prostate cancer survivors. Cancer Causes Control (2016) 0.75

RE: Validation of the brazilian version of the expanded prostate cancer index composite (EPIC) for patients submitted to radical prostatectomy. Int Braz J Urol (2015) 0.75

Predictors of adherence to a 12-week exercise program among men treated for prostate cancer: ENGAGE study. Cancer Med (2016) 0.75

Quality of life in patients with prostate cancer treated with radical image-guided radiotherapy. Contemp Oncol (Pozn) (2014) 0.75

Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies. BMC Cancer (2014) 0.75

Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study. BMC Cancer (2013) 0.75

Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial. Trials (2015) 0.75

Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. Rehabil Oncol (2016) 0.75

Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer. Radiat Oncol (2014) 0.75

Rectal bleeding after radiation therapy for endometrial cancer. Radiother Oncol (2015) 0.75

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Rep Oncol (2016) 0.75

A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology (2015) 0.75

Early detection and management of symptoms using an interactive smartphone application (Interaktor) during radiotherapy for prostate cancer. Support Care Cancer (2017) 0.75

Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients. Health Qual Life Outcomes (2016) 0.75

Focal low-dose rate brachytherapy for the treatment of prostate cancer. Cancer Manag Res (2013) 0.75

Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol. BMJ Open (2016) 0.75

Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open (2016) 0.75

Cancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches. J Cancer Surviv (2017) 0.75

Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings. Patient (2017) 0.75

Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: study protocol of a stepped-wedge cluster randomised controlled trial. BMJ Open (2017) 0.75

Income and health-related quality of life among prostate cancer patients over a one-year period after radical prostatectomy: a linear mixed model analysis. Qual Life Res (2017) 0.75

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14

Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med (2009) 5.82

A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol (2012) 5.59

Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30

Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res (2004) 4.33

Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol (2012) 4.08

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78

Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73

Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol (2008) 3.29

The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol (2010) 2.82

Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol (2005) 2.71

Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol (2009) 2.64

Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2009) 2.50

Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol (2011) 2.48

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42

Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res (2011) 2.42

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol (2009) 2.35

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol (2013) 2.32

Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26

The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26

The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol (2002) 2.25

Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23

Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol (2008) 2.23

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21

Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol (2007) 2.17

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol (2005) 2.15

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res (2005) 2.04

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol (2013) 2.02

Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol (2003) 2.00

The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int (2013) 1.99

The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97

ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96

What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89

Paternity following treatment for testicular cancer. J Natl Cancer Inst (2005) 1.87

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84

A systematic review of web-based interventions for patient empowerment and physical activity in chronic diseases: relevance for cancer survivors. J Med Internet Res (2013) 1.82

Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol (2006) 1.78

Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol (2012) 1.74

Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol (2007) 1.73

Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72

Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71

The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70

The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer (2011) 1.69

Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol (2012) 1.68

Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis. Psychooncology (2011) 1.68

Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol (2003) 1.68

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62

Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res (2012) 1.62

Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer (2007) 1.62

Comparing higher order models for the EORTC QLQ-C30. Qual Life Res (2011) 1.60

Transfusions at home in patients with myelodysplastic syndromes. Leuk Res (2012) 1.59

Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 1.58

Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol (2008) 1.57

A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int (2012) 1.57

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57

The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol (2006) 1.55

Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol (2006) 1.55

Vasogenic erectile dysfunction Topiramate-induced. Clin Neurol Neurosurg (2011) 1.52

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52

Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol (2006) 1.52

Long-term cardiac mortality after hypofractionated radiation therapy in breast cancer. Int J Radiat Oncol Biol Phys (2013) 1.52

Health related quality of life in men with prostate cancer. J Urol (2003) 1.51

A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer (2008) 1.50

Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv (2014) 1.49

Factors predicting continence recovery 1 month after radical prostatectomy: results of a multicenter survey. Int J Urol (2011) 1.49

Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol (2013) 1.49

Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol (2005) 1.48

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48

Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer (2008) 1.47

Do quality-of-life randomized clinical trials support clinicians in their decision-making? J Clin Oncol (2002) 1.45

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev (2010) 1.43

Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol (2010) 1.43

Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol (2014) 1.42

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol (2009) 1.42

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41

In vivo microwave-induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. BJU Int (2010) 1.40